Illumina, Inc. (ILMN) Income Statement

The 9.7% revenue growth in Q2 2026 marks a clear acceleration from the prior quarter's 4.8% and the negative prints of 2025, indicating that the NovaSeq X upgrade cycle and clinical adoption may be gaining traction. However, the TTM revenue decline of -0.8% underscores that the recovery is still nascent, and investors should monitor whether this momentum can be sustained across multiple quarters. The raised guidance suggests management's confidence, but the durability of clinical-driven demand remains unproven.

The stability of gross margins around 66-67% suggests that Illumina has so far defended its pricing on consumables, even as competitors like MGI and Ultima Genomics target the high-throughput segment. The slight dip from the 69% peak in Q3 2024 may indicate early pressure from mix shifts or promotional activity, but the overall trajectory appears controlled. The key risk is whether sustained competitive entry forces a more pronounced margin compression, which would challenge the razor-and-blade model.

The sequential improvement in operating margin from 19.2% to 21.1% in Q2 2026 suggests that the company is beginning to realize operating leverage as revenue scales, with SG&A and R&D growing at a slower pace than gross profit. This is a positive sign for the post-GRAIL refocused strategy, but the sustainability depends on maintaining revenue growth while controlling costs. If clinical momentum falters, the fixed-cost base could quickly reverse this leverage.

The substantial reduction in both R&D and SG&A expenses reflects the company's efforts to streamline operations after the costly GRAIL acquisition and divestiture. While this discipline has contributed to the operating margin expansion, the R&D cut may raise concerns about future innovation and competitive positioning, especially as rivals invest in next-generation technologies. The balance between cost efficiency and maintaining a robust pipeline will be critical.

The massive losses in Q2 2024 were primarily due to impairment and restructuring charges associated with the GRAIL divestiture, which obscured the underlying profitability of the core sequencing business. The sharp rebound in Q3 2024, with operating income of $741M, reflects the removal of these one-time items and the beginning of a cleaner earnings profile. This inflection point appears to have reset the company's financial trajectory, but the long-term impact will depend on the success of the NovaSeq X transition and competitive dynamics.